Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CCL2 | P13500 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL186866 | 0.76 | HTR2A (0.41) | BRD4CCL2RETHTR2A | |
| SCHEMBL631657 | 0.74 | HTR2A (0.31) | HTR2A | |
| SCHEMBL6657234 | 0.74 | HTR2A (0.40) | BRD4CCL2RETHTR2A | |
| Bromide SCHEMBL28346507 | 0.74 | HTR2A (0.40) | BRD4CCL2RETHTR2A | |
| SCHEMBL30122871 | 0.74 | HTR2A (0.40) | BRD4CCL2RETHTR2A | |
| Benzene SCHEMBL28389034 | 0.74 | SIGMAR1 (0.42) | BRD4CCL2RETHTR2A | |
| SCHEMBL3862739 | 0.73 | MAOA (0.32) | HTR2A | |
| SCHEMBL3048014 | 0.73 | HTR2A (0.30) | HTR2A | |
| Hydrochloric Acid SCHEMBL7076883 | 0.73 | BRD4 (0.39) | BRD4CCL2RETHTR2A | |
| SCHEMBL1547704 | 0.73 | HTR2A (0.30) | HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1703797-A4 | TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kappaB ACTIVITY AND USE THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2009-01-14 | — | — | EP | claimed |
| EP-1534273-A4 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2007-08-22 | — | — | EP | claimed |
| EP-1703797-A2 | TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-κB ACTIVITY AND USE THEREOF | Bristol-Myers Squibb Company (US) | 2006-09-27 | — | — | EP | claimed |
| WO-2005072132-A2 | TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-κB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-11 | — | — | WO | claimed |
| EP-1534273-A2 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD | Bristol-Myers Squibb Company (US) | 2005-06-01 | — | — | EP | claimed |
| WO-2004009017-A2 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-29 | — | — | WO | claimed |
| EP-1019046-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM (US) | 2002-11-27 | — | — | EP | claimed |
| EP-1019046-A1 | PROTEASE INHIBITORS | Smithkline Beecham (US) | 2000-07-19 | — | — | EP | claimed |
| WO-1998048799-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-05 | — | — | WO | claimed |
| US-4772534-A | PHOTORESISTS | FUJI PHOTO FILM CO., LTD. (JP) | 1988-09-20 | — | — | US | claimed |
| US-20160343956-A1 | ORGANIC SOLAR CELL AND METHOD FOR MANUFACTURING SAME | LG CHEMICAL LTD (KR) | 2016-11-24 | — | — | US | disclosed |
| EP-2295421-B2 | AROMATIC AMINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME | IDEMITSU KOSAN CO (JP) | 2016-04-06 | — | — | EP | disclosed |
| EP-2738138-A2 | Graphene derivatives, transparent conductive films, organic electroluminescent devices, methods of preparing the graphene derivatives and methods of preparing anode layers of the devices | Boe Technology Group Co. Ltd. (CN) | 2014-06-04 | — | — | EP | disclosed |
| US-20130331583-A1 | FUNCTIONALIZED ANTHRACENE-CAPPED OLIGOTHIOPHENES AND ORGANIC SEMICONDUCTORS BASED ON THE SAME, USE THEREOF | Institute of Chemistry, Chinesse Academy of Sciences | 2013-12-12 | — | — | US | disclosed |
| EP-2295421-B1 | AROMATIC AMINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME | IDEMITSU KOSAN CO (JP) | 2013-02-20 | — | — | EP | disclosed |
| EP-0166692-A2 | Substituted azabicycloheptanes, their use, pharmaceutical compositions comprising them and process for the preparation of the compounds | CIBA-GEIGY AG (CH) | 1986-01-02 | — | — | EP | disclosed |
| EP-0125756-A2 | Fused imidazole compounds, processes for the preparation thereof and pharmaceutical compositions containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-11-21 | — | — | EP | disclosed |
| EP-0115156-A2 | Light sensitive composition | FUJI PHOTO FILM CO., LTD. (JP) | 1984-08-08 | — | — | EP | disclosed |
| EP-0108709-A2 | Polyalkyl piperidines | CIBA-GEIGY AG (CH) | 1984-05-16 | — | — | EP | disclosed |
| EP-0104146-A1 | Colour-photographic recording material | CIBA-GEIGY AG (CH) | 1984-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160343956-A1 | ORGANIC SOLAR CELL AND METHOD FOR MANUFACTURING SAME | DSG1, VCL, SUN2 | BRD4 4082/4885CCL2 4131/4885RET 4198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.